Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer

Cell Death and Disease

Volumn 4, Issue 12, 2013, Pages

  Riley, J S ^a   Hutchinson, R ^a   McArt, D G ^a   Crawford, N ^a   Holohan, C ^a   Paul, I ^a   Van Schaeybroeck, S ^a   Salto Tellez, M ^a   Johnston, P G ^a   Fennell, D A ^b   Gately, K ^c   O'Byrne, K ^c   Cummins, R ^d   Kay, E ^d   Hamilton, P ^a   Stasik, I ^a   Longley, D B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c ST JAMES S HOSPITAL   (Ireland)

^d BEAUMONT HOSPITAL   (Ireland)

Author keywords

caspase 8; FLIP; HDAC inhibitor; non small cell lung cancer; TRAIL

Indexed keywords

ACY 775; BIRINAPANT; CASPASE 3; CASPASE 8; CISPLATIN; DEATH RECEPTOR; ENTINOSTAT; FLICE INHIBITORY PROTEIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PROCASPASE 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS; CELL VIABILITY; CYTOPLASM; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; VERY ELDERLY;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; RETROSPECTIVE STUDIES;

EID: 84891772080     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.481     Document Type: Article

References (41)

1. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2013; 332: 141-150
2. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190
3. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448
4. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15: 3970-3977
5. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003; 9: 3397-3405
6. den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013; 332: 194-201
7. Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K et al. Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 2009; 16: 1352-1361
8. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, Redmond K et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012; 19: 1317-1327
9. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, Hacker S et al. Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 2012; 31: 4677-4688
10. Hurwitz JL, Stasik I, Kerr EM, Holohan C, Redmond KM, McLaughlin KM et al. Vorinostat/ SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur J Cancer 2012; 48: 1096-1107
11. Paul I, Chacko AD, Stasik I, Busacca S, Crawford N, McCoy F et al. Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death Dis 2012; 3: E449
12. Belani CP, Langer C. First-line chemotherapy for NSCLC: An overview of relevant trials. Lung Cancer 2002; 38(Suppl 4): 13-19
13. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98
14. Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, Longley DB et al. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis 2011; 16: 311-320
15. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010; 6: 238-243
16. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007; 5: 981-989
17. McLornan D, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK et al. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol 2013; 160: 188-198
18. Ashkenazi A. Directing cancer cells to self-destruct with pro-Apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001-1012
19. Fulda S, Vucic D, Targeting IAP. proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124
20. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 2013; 13: 455-465
21. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132
22. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther 2002; 1: 65-69
23. Logan AE, Wilson TR, Fenning C, Cummins R, Kay E, Johnston PG et al. In vitro and in vivo characterisation of a novel c-FLIP-Targeted antisense phosphorothioate oligonucleotide. Apoptosis 2010; 15: 1435-1443
24. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008; 105: 11317-11322
25. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-And TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 2006; 15: 227-230
26. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006; 43: 425-434
27. Rao-Bindal K, Koshkina NV, Stewart J, Kleinerman ES. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. Curr Cancer Drug Targets 2013; 13: 411-422
28. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect. Invest New Drugs 2010; 28(Suppl 1): S3-20
29. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51
30. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 2007; 26: 5541-5552
31. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125-133
32. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923-3931
33. Blumenschein GR Jr., Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008; 26: 81-87
34. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9(10 Pt 1): 3578-3588
35. Kavanaugh SM, White LA, Kolesar JM. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 2010; 67: 793-797
36. Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs 2011; 20: 1455-1467
37. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 56-62
38. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008; 8: 782-798
39. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-3451
40. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM et al. c-FLIP: A key regulator of colorectal cancer cell death. Cancer Res 2007; 67: 5754-5762
41. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55